Resources from the same session
1764O - Timing of radiotherapy (RT) after radical prostatectomy (RP): Final results of RADICALS RT randomised controlled trial
Presenter: Noel Clarke
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
1765O - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: William Kelly
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1764O and 1765O
Presenter: Shahneen Sandhu
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
LBA84 - Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)
Presenter: Louise Emmett
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
1770O - Refining risk stratification in patients undergoing radiotherapy (RT) and long-term (lt) ADT for high-risk/locally advanced prostate cancer (HR/LA-PC): An individual patient data (IPD) analysis of randomized controlled trials (RCTs) from the ICECaP consortium
Presenter: Praful Ravi
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA84 and 1770O
Presenter: Daniel Heinrich
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Proffered Paper session - Genitourinary tumours, prostate
Resources:
Slides
Webcast